Novavax will provide adjuvant Matrix-M for vaccine research with 3-year partnership
.png)
Novavax, developers behind the Matrix-M adjuvant, have entered into an agreement with the Bill and Melinda Gates Medical Research Institute to provide the adjuvant in preclinical vaccine research.
Biotechnology company Novavax have partnered with the Bill and Melinda Gates Research Institute in a 3-year agreement to provide the adjuvant Matrix-M for use in preclinical vaccine research. Adjuvants are ingredients in vaccines that enhance the immune system’s response, resulting in broader and longer-lasting immunity towards pathogens.
Matrix-M, in particular, enhances the entry of antigen-presenting cells at the injection site, promoting their production at local lymph nodes. The ingredient is a key component in Novavax’s COVID-19 vaccine, and the company has begun investigations into its use for vaccines in other disease areas. The saponin-based Matrix-M has also been utilised in global clinical and preclinical trials for human and animal vaccine development.
The Bill and Melinda Gates Research Institute will be partnering with Novavax to further develop their own commitments to developing biomedical interventions addressing global health needs. “The Bill and Melinda Gates Research Institute is committed to developing biomedical interventions that address global health concerns for those in the greatest need,” stated Emilio Emini, PhD, CEO of the Bill and Melinda Gates Medical Research Institute. “We look forward to working with Novavax’s Matrix-M adjuvant in some of our early-stage vaccine programs.”
Novavax is committed to the discovery and development of vaccines against infectious diseases, as well as their commercialisation. “We are excited to partner with the Bill and Melinda Gates Medical Research Institute to include our unique technology in their public health-focused vaccine research efforts,” John Jacobs, President and CEO of Novavax, commented. “Our Matrix-M adjuvant is proven to enhance and broaden the immune system response when included in vaccines and is already a key component of COVID and malaria vaccines on the market today. We look forward to partnering more broadly with a variety of organisations so that our technology can benefit vaccine development across many disease areas.”
Source: Novavax Announces Agreement with Bill & Melinda Gates Medical Research Institute to Include Matrix-M™ Adjuvant as Potential Component in Vaccine Research [Accessed June 6, 2023] https://ir.novavax.com/2023-06-05-Novavax-Announces-Agreement-with-Bill-Melinda-Gates-Medical-Research-Institute-to-Include-Matrix-M-TM-Adjuvant-as-Potential-Component-in-Vaccine-Research
Related News
-
News CPHI Americas 2025 - From the Floor
Our From the Floor live blog is back in Philadelphia for this year’s CPHI, this time under the new name CPHI Americas to embrace and represent the whole of the pharmaceutical supply chain from north to south.
-
News Women in Pharma: Unlocking patient inclusion at CPHI Americas
Our monthly Women in Pharma series highlights the influential lives and works of impactful women working across the pharmaceutical industry, and how the industry can towards making the healthcare industry and workplace more equitable and inclusive.&nbs... -
News Tracking Innovation with Thermo Fisher Scientific: CPHI Americas Track Sponsor interview
As we gear up for CPHI Americas from May 20-22, 2025 at the Philadelphia Convention Center, we sat down with Track Sponsor Thermo Fisher Scientific to discuss the future of bioproduction in pharma.
-
News Welcome back to the CPHI Exhibitor Spotlight!
We’re continuing our journey through the standout companies heading to CPHI Americas 2025, and next up is Adare - a global leader known for turning complex formulation challenges into innovative, patient-centric solutions.
-
News PhRMA trade association issues comments on Section 232 investigation
The Pharmaceutical Research and Manufacturers of America (PhRMA), an American trade association representing groups in the pharmaceutical industry, issued a letter on May 6, 2026 to the Department of Commerce regarding the Section 232 National Security... -
News Pharmaceutical Packaging Market Prospects: Shifting regional policies
The pharmaceutical packaging industry is experiencing significant transformation in 2025, driven by regulatory changes, supply chain challenges, and sustainability initiatives. The US BIOSECURE Act, passed through the House of Representatives in Septem... -
News Executive order to elevate US pharma manufacturing signed by Trump
On Monday, May 5, US President Trump signed an executive order to reduce regulatory barriers for domestic US pharmaceutical manufacturing, including key ingredients and materials for manufacturing prescription drugs.
-
News Merck KGaA to buy US biotech SpringWorks for US$3.9 billion
The German multinational pharmaceutical company Merck KGaA have signed a deal to buy US biotech company SpringWorks Therapeutics at an equity value of US$3.9 billion in a move to add rare cancer therapeutics to their pipelines.